Baseline susceptibility of primary human immunodeficiency virus type 1 to entry inhibitors

被引：90

作者：

Labrosse, B

Labernardière, JL

Dam, E

Trouplin, V

Skrabal, K

Clavel, F

Mammano, F

机构：

[1] Hop Bichat Claude Bernard, Unite Rech Antivirale, INSERM, U552, F-75018 Paris, France

[2] Viralliance SAS, Paris, France

来源：

JOURNAL OF VIROLOGY | 2003年 / 77卷 / 02期

关键词：

D O I：

10.1128/JVI.77.2.1610-1613.2003

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

Human immunodeficiency virus type 1 plasma viruses from 29 entry inhibitor-naive patients were characterized for their susceptibilities to T-20, AMD3100, and RANTES. A strikingly wide range of susceptibilities to T-20 was observed that was influenced by coreceptor usage but not by the susceptibilities of the viruses to inhibitors that target the chemokine receptors or by polymorphisms in the gp41 N helix.

引用

页码：1610 / 1613

页数：4

共 50 条

[31] Stoichiometry of envelope glycoprotein trimers in the entry of human immunodeficiency virus type 1
Yang, XZ
Kurteva, S
Ren, XP
Lee, S
Sodroski, J
JOURNAL OF VIROLOGY, 2005, 79 (19) : 12132 - 12147
[32] The rise and fall of polyanionic inhibitors of the human immunodeficiency virus type 1
Pirrone, Vanessa
Wigdahl, Brian
Krebs, Fred C.
ANTIVIRAL RESEARCH, 2011, 90 (03) : 168 - 182
[33] Synthesis of nucleosidyl rifamycins as inhibitors of human immunodeficiency virus type 1
Bartolucci, C
Cellai, L
Mannina, L
Marzano, M
Brufani, M
Filocamo, L
Messina, S
Brizzi, V
Benedetto, A
DiCaro, A
ANTIVIRAL CHEMISTRY & CHEMOTHERAPY, 1997, 8 (03): : 215 - 221
[34] Antimalarial activity of human immunodeficiency virus type 1 protease inhibitors
Parikh, S
Gut, J
Istvan, E
Goldberg, DE
Havlir, DV
Rosenthal, PJ
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2005, 49 (07) : 2983 - 2985
[35] Inhibition of human immunodeficiency virus type-1 by cdk inhibitors
Irene Guendel
Emmanuel T Agbottah
Kylene Kehn-Hall
Fatah Kashanchi
AIDS Research and Therapy, 7
[36] Virus isolates during acute and chronic human immunodeficiency virus type 1 infection show distinct patterns of sensitivity to entry inhibitors
Rusert, P
Kuster, H
Joos, B
Misselwitz, B
Gujer, C
Leemann, C
Fischer, M
Stiegler, G
Katinger, H
Olson, WC
Weber, R
Aceto, L
Günthard, HF
Trkola, A
JOURNAL OF VIROLOGY, 2005, 79 (13) : 8454 - 8469
[37] Synthesis of nucleusidyl rifamycins as inhibitors of human immunodeficiency virus type 1
Bartolucci, C.
Cellai, L.
Mannina, L.
Marzano, M.
Antiviral Chemistry & Chemotherapy, 8 (03):
[38] Nucleoside inhibitors of human immunodeficiency virus type 1 reverse transcriptase
Sharma, PL
Nurpeisov, V
Hernandez-Santiago, B
Beltran, T
Schinazi, RF
CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2004, 4 (09) : 895 - 919
[39] Inhibition of human immunodeficiency virus type-1 by cdk inhibitors
Guendel, Irene
Agbottah, Emmanuel T.
Kehn-Hall, Kylene
Kashanchi, Fatah
AIDS RESEARCH AND THERAPY, 2010, 7
[40] env chimeric virus technology for evaluating human immunodeficiency virus susceptibility to entry inhibitors (vol 46, pg 3954, 2002)
Fikkert, V
Cherepanov, P
Van Laethem, K
Hantson, A
Van Remoortel, B
Pannecouque, C
De Clercq, E
Debyser, Z
Vandamme, AM
Witvrouw, M
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2003, 47 (03) : 1177 - 1177

← 1 2 3 4 5 →